Search

457 Result(s)
Sort by

Respiratory Diseases

Respiratory Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
Cardiometabolic Diseases

Cardiometabolic Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
Immunology

Immunology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
FDA-approves-nintedanib-in-SSc-ILD

FDA-approves-nintedanib-in-SSc-ILD

FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
International Women's Day

International Women's Day

We celebrate International Women’s Day with this year’s UN Women motto being “Gender Equality Today for a Sustainable Tomorrow”
FDA-CRL-T1D

FDA-CRL-T1D

US FDA issues complete response letter for treatment of adults with type 1 diabetes
Health Equity: No distance is too far

Health Equity: No distance is too far

India is hosting the G20 summit. The leading theme of the G20 summit emphasizes health equity and sustainability as part of the agenda. How we provide access to healthcare for rural areas in India.
emperor-reduced-heart-failure-toplineresults

emperor-reduced-heart-failure-toplineresults

Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction
GioTag Final Data

GioTag Final Data

Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients